Advances and challenges in targeting FGFR signalling in cancer
Crossref DOI link: https://doi.org/10.1038/nrc.2017.8
Published Online: 2017-03-17
Published Print: 2017-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Babina, Irina S.
Turner, Nicholas C.
Text and Data Mining valid from 2017-03-17
Article History
First Online: 17 March 2017
Competing interests
: N.C.T. has received advisory board honoraria from AstraZeneca, Novartis and Servier. I.S.B. declares no competing interests.